A phase 2 study reveals promising efficacy and safety of TKI and inotuzumab ozogamicin therapy for newly diagnosed Ph+ ALL, achieving high response rates.
Anand A. Patel, MD
Advertisement
Anand A. Patel, MD, is an assistant professor of medicine at the University of Chicago.
Articles by Anand A. Patel, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
3
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
4
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
5